NCT02608073View on ClinicalTrials.gov

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Nasopharyngeal Cancer
Interventions
DRUG

Capecitabine

Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

DRUG

Cisplatin

Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

Trial Locations (9)

106

Taipei

333

Kueishan

852

Hong Kong

10330

Bangkok

10400

Bangkok

50603

Kuala Lumpur

55284

Yogyakarta

Unknown

Hong Kong

00112

Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02608073 - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter